Taxus Cardium Pharmaceuticals Group Inc., formerly Cardium Therapeutics, Inc., is a development-stage regenerative medicine biotechnology company. The Company is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address unmet medical needs. The Company�s products include Generx and Excellagen. Generx, Cardium�s lead Phase III clinical study product candidate, is a transformative disease-modifying angiogenic gene therapy growth factor therapeutic that is being developed for the treatment of Cardiac Microvascular Insufficiency (CMI). Excellagen is Aseptic Pharmaceutically-Formulated Fibrillar Collagen developed based on technology through its acquisition of the Tissue Repair Company .The Company�s wholly owned subsidiaries include Tissue Repair Company, To Go Brands, Inc. and LifeAgain Insurance Solutions, Inc., an advanced medical data analytics business.